Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | POLB | P06746 | 5/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.58 |
| ▸ | CTSB | P07858 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.49 |
| ▸ | CASP6 | P55212 | 3/20 | 0.48 |
| ▸ | CTDSP1 | Q9GZU7 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NSD2 | O96028 | 2/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3140547 | 0.86 | ALDH1A1 (0.67) | ALDH1A1POLBKDM4EHPGDMAPK1 | |
| SCHEMBL1788237 | 0.84 | ALDH1A1 (0.59) | ALDH1A1POLBKDM4EHPGDMAPK1 | |
| SCHEMBL2757862 | 0.81 | KMT2A (0.65) | ALDH1A1POLBKDM4EHPGDTDP1 | |
| SCHEMBL130491 | 0.80 | KDM4E (0.74) | ALDH1A1POLBKDM4EHPGDMAPK1 | |
| SCHEMBL1786657 | 0.79 | POLB (0.62) | ALDH1A1POLBKDM4EHPGDMAPK1 | |
| SCHEMBL15714465 | 0.76 | ALDH1A1 (1.00) | ALDH1A1POLBKDM4EHPGDMAPK1 | |
| SCHEMBL5323825 | 0.75 | ALDH1A1 (0.57) | ALDH1A1POLBKDM4EHPGDMAPK1 | |
| SCHEMBL28034614 | 0.74 | MAPT (0.51) | ALDH1A1POLBKDM4EHPGDMAPK1 | |
| SCHEMBL15123245 | 0.74 | IP6K1 (0.66) | ALDH1A1POLBKDM4EHPGDMAPK1 | |
| SCHEMBL3045754 | 0.74 | ALDH1A1 (0.73) | ALDH1A1POLBKDM4EHPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497643-B2 | Endo-S2 mutants as glycosynthases, method of making and use for glycoengineering of glycoproteins | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2025-12-16 | — | — | US | disclosed |
| US-12187662-B2 | FOXM1 inhibitor compositions and methods of using the same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240216345-A1 | NEW METHOD FOR TREATING DENGUE VIRUS INFECTION | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2024-07-04 | — | — | US | disclosed |
| US-11845970-B2 | Endo-S2 mutants as glycosynthases, method of making and use for glycoengineering of glycoproteins | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2023-12-19 | — | — | US | disclosed |
| EP-3402815-B1 | ENDO-S2 MUTANTS AS GLYCOSYNTHASES, METHOD OF MAKING AND USE FOR GLYCOENGINEERING OF GLYCOPROTEINS | UNIV MARYLAND (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230348947-A1 | ENDO-S2 MUTANTS AS GLYCOSYNTHASES, METHOD OF MAKING AND USE FOR GLYCOENGINEERING OF GLYCOPROTEINS | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230313325-A1 | METHODS FOR DETECTION OF PATHOGENIC INFECTIONS USING RED BLOOD CELL-CONTAINING PATIENT SAMPLES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2023-10-05 | — | — | US | disclosed |
| US-11643450-B2 | Chemoenzymatic glycoengineering of antibodies and Fc fragments thereof | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-05-09 | — | — | US | disclosed |
| EP-4146820-A1 | METHODS FOR DETECTION OF PATHOGENIC INFECTIONS USING RED BLOOD CELL-CONTAINING PATIENT SAMPLES | The Trustees of The University of Pennsylvania (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-2812442-B9 | CHEMOENZYMATIC GLYCOENGINEERING OF ANTIBODIES AND FC FRAGMENTS THEREOF | UNIV MARYLAND (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-2607357-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | Astrazeneca AB (SE) | 2013-06-26 | — | — | EP | disclosed |
| US-20120115845-A1 | THERAPEUTIC AGENTS | ALLEN JACK MCQUEEN (GB) | 2012-05-10 | — | — | US | disclosed |
| US-20110124621-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | US | disclosed |
| CN-101883762-A | Benzothiazoles as modulators of growth hormone releasing hormone receptors | ASTRAZENECA AB | 2010-11-10 | — | — | CN | disclosed |
| EP-2205576-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2010-07-14 | — | — | EP | disclosed |
| US-20090186870-A1 | Therapeutic Agents - 802 | ASTRAZENECA AB (SE) | 2009-07-23 | — | — | US | disclosed |
| WO-2009047558-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | WO | disclosed |
| US-20080039428-A1 | Antiretroviral combination therapy | PANACOS PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20070232684-A1 | Compounds for inhibition of HIV infection by blocking HIV entry | NEW YORK BLOOD CENTER | 2007-10-04 | — | — | US | disclosed |
| US-7241803-B2 | Compounds for inhibition of HIV infection by blocking HIV entry | NEW YORK BLOOD CENTER (US) | 2007-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232684-A1 | Compounds for inhibition of HIV infection by blocking HIV entry | SDF4, NUCB2, CXCR4 | ALDH1A1 4651/4885POLB 3253/4885KDM4E 4676/4885 |
| US-20120115845-A1 | THERAPEUTIC AGENTS | GPR119, MC2R, MC4R | ALDH1A1 650/4885POLB 4524/4885KDM4E 3215/4885 |
| US-20090186870-A1 | Therapeutic Agents - 802 | GPR119, SLC5A2, MC2R | ALDH1A1 918/4885POLB 3987/4885KDM4E 3524/4885 |
| US-20110124621-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | GPR119, GHSR, GLP1R | ALDH1A1 2084/4885POLB 4687/4885KDM4E 1188/4885 |
| US-12187662-B2 | FOXM1 inhibitor compositions and methods of using the same | FOXM1, FOXO1, TP53 | ALDH1A1 2437/4885POLB 356/4885KDM4E 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.